Background. Morbidity and mortality are higher among human immunodeficiency virus (HIV) exposed but uninfected (HEU) infants than unexposed infants, particularly if the mother had a low CD4 count. We investigated the possible association between maternal immune depression during pregnancy and the risk of infection in HEU infants in the national French Perinatal Cohort (EPF).
observations from large cohorts in industrialized countries, a Belgian study showed that streptococcus B infection was 19 times more frequent among HEU infants than other infants [10] . There are several possible reasons for these findings, including a social context of poverty and limited access to care, imbalanced maternal microbial ecology, or immunodeficiency in HEU infants. Several quantitative and qualitative immunological abnormalities have indeed been observed in these children [11] , including altered dendritic cell phenotype [12, 13] , CD4/8 lymphopenia [14] [15] [16] [17] , reduction of naive or memory T cells [14, 18, 19] , reduced size of the thymus [20] , cytokine production [14, 21] , increased apoptosis of T cells [22] , and altered cellular immune response to bacille Calmette-Guérin [23] . Data relevant to B lymphocyte function and production of specific antibodies after vaccination of HEU children are contradictory. Humoral immunity is, in some cases, apparently impaired [24] ; however, in a large South African study, titers of antibodies against pertussis and pneumococcus after immunization were higher than in controls [25] . The main consistent finding is of impaired humoral immunity that is passively transferred from the mother to the child by placental transfer of maternal immunoglobulin (Ig) G [25] [26] [27] [28] [29] [30] . Except for this passively transmitted humoral immune deficiency, it is difficult to dissect the role of the maternal disease itself from the potentially or putatively deleterious effects of HIV antigens to which the uninfected fetus is exposed [31] , possible coinfections [32] , and antiretroviral therapy (ART) [11, [33] [34] [35] [36] .
We used the national French Perinatal Cohort (EPF) to study the relationships between maternal immunological status and serious infectious morbidity of HEU infants living in a highincome country.
METHODS
The French Perinatal Cohort: France REcherche Nord&Sud Sida-HIV Hepatites CO1/CO11-EPF Since 1986, EPF has prospectively enrolled pregnant HIVinfected women delivering in 90 centers throughout France. The methodology has been described elsewhere [37] . Mothers are followed until delivery and children are followed from birth to 1, 3, 6, 12 , and 18-24 months after birth, and then, if HIVinfected, every 6 months. Clinicians are encouraged to follow current French national guidelines [38] , without any specific recommendations from EPF, and there is no childhood immunization specifically given due to HIV exposure. The EPF is funded by the France REcherche Nord&Sud Sida-HIV Hepatites (ANRS) and has been approved by the Hôpital Cochin institutional review board and the French computer database watchdog commission.
Study Population
All neonates included in the EPF born to HIV-1-infected mothers between 1 January 2002 and 31 December 2010, at 28 weeks of gestational age or more, and not breastfed were eligible for this study if they were HIV-uninfected (N = 8216 infants). An infant was considered to be uninfected if serologically negative at ≥18 months and/or if 2 separate samples after the neonatal prophylactic treatment were HIV-1 polymerase chain reaction negative. Infants with undetermined HIV status, missing maternal CD4 cell count, or missing follow-up duration were excluded (Figure 1 ).
Primary Outcome
The primary outcome was the first serious infection during the first year of life. All clinical events and hospitalizations were recorded at each routine visit to the pediatric center, using standardized questionnaires that included items for infections, organ systems involved, and infectious agents responsible.
An infection was defined as "serious" if it was the main reason for hospitalization or death. Infections, as recorded prospectively by clinicians who reported them in standardized questionnaires, were retrospectively classified by both epidemiologists and pediatricians (blind to maternal and neonatal characteristics) into the following 3 categories: bacterial, viral, and fungal/parasitic. Infection categories were considered as proven if the causative agent was identified (from blood or local samples) or probable in cases of expert judgment alone. All infections with no reported causative agent and no unambiguous consensual identification were classified as "undetermined" (see Supplementary Table 1) . Prenatal infections were not studied. Reasons for loss to follow-up, especially death, are reported in the EPF questionnaire when known by clinicians at participating centers.
Primary Exposure
The main exposure variable was the maternal CD4 cell count closest to (before or no later than 1 week after) delivery categorized into the following 3 classes: <350, 350-499, ≥500 cell/mm 3 .
Statistical Analysis
Fisher exact or χ 2 tests were used to compare distributions of categorical variables. Student t test or Wilcoxon rank test was used to compare means of continuous variables. The Kaplan-Meier survival method and proportional hazards survival Cox models were used to study the association between maternal CD4 cell count and the first occurrence of serious infection before age 1 year (event). Follow-up was censored at 12 months or the last available data before age 1 year. To study associations with each type of serious infection (bacterial, viral, fungal/parasitic, undetermined), follow-up was also censored at the first occurrence of any other type, considered as competing events. Adjusted hazard ratios (aHRs) measuring associations between maternal CD4 count and serious bacterial and viral infections were estimated in separate multivariate Cox models. The number of fungal/parasitic infections was too small to fit a specific model. Multivariate models were adjusted for known risk factors of infections recorded in the EPF cohort, for type of ART ( potentially linked to infant hematological parameters), and for other noncollinear variables found to be associated with P < .2 in bivariate analysis. We also adjusted for parity in order to account for correlations between infants born to the One infant died at 9 months (severe diarrhea with dehydration).
c Two infants died, 1 at 8 months (respiratory failure subsequent to viral infection and suffering from infantile spinal muscular amyotrophy) and 1 at 1 year (viral pericarditis).
d One death of unknown cause at 5 months, 1 death from arterial pulmonary hypertension at 9 months.
e One death due to cardiac failure at 6 months. Abbreviations: GW, gestational weeks; HIV, human immunodeficiency virus. same mother. In the main analysis, we did not adjust for neonatal neutropenia or lymphopenia, including neonatal CD4, as these are potentially intermediate factors on the pathway between maternal immunity and infection risk. Sensitivity analyses were performed to check the robustness of results of the main analysis (see "Results" section). SAS statistical software (version 9.3; SAS Institute Inc., Cary, NC) was used for analyses; Proc FREQ was used for χ 2 and Fisher tests; Proc LIFETEST was used for Kaplan-Meier survival curves; and Proc PHREG was used for Cox proportional hazard ratios models. The cutoff for statistical significance was P < .05.
RESULTS

Population
Between January 2002 and December 2010, 7638 infants born to 5871 HIV-1-infected mothers were included in the analysis. Most (88.1%; n = 6729) were followed up for at least 365 days. Fourteen percent (n = 1072) of neonates were premature (<37 gestational weeks [GW] ), including 154 who were severely premature (between 28 and 32 GW); maternal CD4 count was not associated with prematurity. Maternal CD4 count was ≥500/mm 3 for 43.9% (n = 3353) of these neonates, between 350 and 499/mm 3 for 28.2% (n = 2155), and <350/mm 3 for 27.9%
(n = 2130); the median infant follow-up durations were similar in these 3 subgroups (Table 1) . Low maternal CD4 count was significantly more frequent among women originating from sub-Saharan Africa, those who were active drug users, and those who delivered with higher maternal viral load or by caesarean section than among other women. CD4 count was also significantly lower among women receiving combination ART (cART) than those receiving mono or dual nucleoside reverse transcriptase inhibitors (NRTIs).
Frequency and Description of Serious Infection in Infants
Of the 7638 HEU infants, 699 experienced at least 1 serious infection (as the main reason for hospitalization or death) during their first year of life; there were 813 serious infections (1 to 5 per patient, mean 1.2). Of the 699 first serious infections, 59.5% were classified as viral (54 proven, 362 probable), 22.8% as bacterial (60 proven, 99 probable), 1.1% as fungal or parasitic (5 proven, 3 probable), and 16.6% (n = 116) as undetermined (causative agent unknown or missing data, insufficient clinical data, or no consensual interpretation of the data available). The systems involved and infectious agents isolated are described in Supplementary Table 1 . Twenty-nine percent (46/159) were lower respiratory tract infections (LRTI) ( Table 2) , with 24.5% (n = 39) being pneumonia. One opportunistic infection, that is, pneumocystis (confirmed by bronchioloalveolary lavage as "few cysts in lavage fluid"), was recorded in a 3-month-old infant born preterm (32 GW) . An encapsulated germ was formally identified for 56.7% (34/60) of these confirmed bacterial infections. There were 3 deaths associated with infection-severe diarrhea with major dehydration, viral pericarditis, and respiratory failure associated with viral pneumonitis in a child with infantile spinal muscular atrophy.
The Kaplan-Meier probability of developing a serious infection during the first year of life was 9.3% (95% confidence interval, 8.7%; 10.0%), corresponding to an incidence of 10.1 per 100 person-years and stable throughout the study. The Kaplan-Meier probability at 1 year of life was 5.7% (5.2%; 6.3%) for viral infection, 2.2% (1.9%; 2.6%) for bacterial infection, 0.1% (0.1; 0.2%) for fungal or parasitic infection, and 1.6% (1.3%; 1.9%) for undetermined infections.
Relationships Between Maternal CD4 Count and Serious Infection in Infants: Bivariate and Multivariate Analysis Maternal CD4 count was not significantly associated with the overall incidence of serious infections (log-rank P = .59). However, there was a specific association between maternal CD4 count and serious, proven, or probable bacterial infection (P = .04; Table 3 ) but not serious viral (P = .76), fungal or (9) Maternofetal infection 6.9 (11) 0.5 (2) parasitic (P = .58), or undetermined (P = .28) infections, suggesting that the absence of microbiological identification was not likely to be a differential bias (Figure 2 ). The association between lower maternal CD4 count and higher risk of serious bacterial infection remained constant (but tended to increase) during the first year of life; the interaction between maternal CD4 count and follow-up time was not significant (P = .21; Table 3 ).
We studied the association between maternal CD4 cell count and bacterial infection of the infant by stratifying for site of infection and type of microorganism. Maternal CD4 count was associated with LRTI but not with urogenital bacterial infection (P = .04 and .46, respectively) and with infections due to encapsulated bacteria (Haemophilus, Streptococcus, and Bordetella; P = .03) but not with those due to gram-negative enterobacteria (P = .43).
Infants excluded because of missing maternal CD4 values tended to have profiles (for the main covariates) similar to those of infants with known maternal CD4, and their overall risk of serious infections was not different (P = .59, data not shown). We found no evidence of a specific association between serious bacterial or viral infections and the type of treatment b Interaction between maternal CD4 cell count and follow-up time was computed with the time being coded as the log of time centered about its mean.
c Staphylococcus pneumoniae, Haemophilus, S. agalactiae, and B. pertussis.
d Escherichia coli, Staphylococcus, Clostridium, Klebsiella, and Salmonella.
received by mothers-mono-and bi-therapies vs cART, nor zidovudine vs other NRTI-based combinations. After adjustment in the multivariate Cox model (Tables 4  and 5 ), the maternal CD4 count remained associated with serious bacterial infections but not with viral infections. In particular, the risk of serious bacterial infection was significantly higher for infants of mothers with the lowest rather than the highest CD4 counts-aHR = 1.7 (1.2; 2.6) for CD4 <350/mm 3 and aHR = 1.2 (0.8; 1.9) for CD4 = 350-499/mm 3 ; P = .03.
Also, bacterial infection remained associated with sub-Saharan maternal origin, vaginal delivery, prematurity, male gender, being small for gestational age, and neonatal anemia. Viral infection was independently associated with sub-Saharan maternal origin, multiparity, prematurity, fetal cardiac rhythm abnormalities, and male gender. More economical models gave similar results. Maternal CD4 count was not associated with any of the following variables: neonatal anemia, neutropenia, lymphopenia, and low CD4 cell count at birth or at age 6 months, either before (Table 1) or after adjustment for maternal geographical origin. There was no interaction between maternal CD4 count and gestational age at delivery for the risk of bacterial infection (heterogeneity test P = .50, data not shown). The infant's CD4 cell count at birth was not associated with risk of serious infection (whether bacterial, viral, fungal or parasitic, undetermined, or any; data not shown).
Sensitivity Analysis
The relationship between maternal CD4 count and bacterial infection was not changed by restricting the analysis to term-born infants (overall P = .02) or excluding the 206 infants born to mothers with last maternal CD4 count measured more than 90 days before delivery (P = .03). The relationship between maternal CD4 count and serious bacterial and viral infections remained unchanged by restricting the analysis to the infants born to sub-Saharan mothers (P = .04 and .33, respectively).
In the main analysis, we dichotomized the 699 first serious infections into 4 types, considered as competing events for proportional hazards Cox modeling (159 bacterial, 416 viral, 8 fungal or parasitic, and 116 undetermined); subsequent serious infections were not included. However, 13 of the 540 infants who had a viral, fungal or parasitic, or undetermined first serious infection subsequently developed a serious bacterial infection. Inversely, a serious viral infection subsequently developed in 17 of the 283 infants who had other types of first serious infection. We performed a secondary survival analysis with the first occurrence of each type of infection as the events, ignoring previous history of other types of infection. The results were consistent; serious bacterial infections (aHR = 1. 8 [1.2; 2.7] 
DISCUSSION
We report that the risk of serious bacterial infections among HEU infants during the first year of life is inversely associated with maternal CD4 values during pregnancy. This susceptibility to bacterial infection appears to involve mostly LRTI and infections with encapsulated pathogens, including Haemophilus influenzae and Streptococcus pneumonia. The risk is not limited to the neonatal period and seems to remain stable during the first year of life. In sharp contrast, there was no association between maternal CD4 count and the risk of viral infection. This is the first such study in an industrialized country. The findings suggest that, even in a context of easy and free access to Figure 2 . Kaplan-Meier probability estimates of serious infections in human immunodeficiency virus (HIV)-uninfected infants born to HIV-1-infected mothers, according to microbiological type of infection* and to maternal CD4 cell count (France REcherche Nord&Sud Sida-HIV Hepatites CO1/CO11 2002-2011). *The event was the first occurrence of a serious infection during the first year of life, the various types being considered as competing events. Association with each type of infection was studied separately, follow-up being censored at 12 months, at the time of loss to follow-up, or at the time of any other kind of first serious infection. Blood or local samples were used for microbiological identification of the causes of serious infections, according to clinical recommendations. No biological analyses were conducted specifically for this study. Abbreviations: cHR, crude hazard ratio; CI, confidence interval. healthcare, the relationship between maternal immunity and early pediatric infectious morbidity reported in low-or middle-income countries is a generalized phenomenon [2, 8, 9] .
Our study has several strengths. We considered only infections that led to hospitalization or death, which minimized reporting heterogeneity and limited diagnosis errors and undetermined types. The association with degree of maternal immune suppression was strong for undoubtedly bacterial pneumonia and for infections involving encapsulated bacteria; however, it was not significant for pyelonephritis likely to be associated with gram-negative enterobacteria. Despite the larger number of viral infections compared with bacterial infections, thus with greater statistical power, no association could be detected between maternal CD4 count and gastroenteritis or bronchiolitis, undoubtedly of viral origin, or viral infections in general. The results were robust; they were largely unaffected in sensitivity survival analysis based on the first occurrence of each type of infection rather than the first occurrence of any serious infection primarily dichotomized into 4 types as competing events.
The association between low maternal CD4 count and neonatal bacterial infection was both specific and independent of potential confounding factors after adjustment in multivariate analysis. The sub-Saharan maternal origin, preterm delivery, being small for gestational age, vaginal delivery, male gender, and neonatal anemia remained significantly associated. Maternal origin, preterm delivery, and male gender were associated with both serious bacterial and serious viral infections, whereas high parity was associated only with serious viral infection, possibly due to the increased risk of viral contamination from other infants (brothers and sisters) in the home [9] . The association between bacterial infection and vaginal delivery may reflect obstetric factors that were not controlled for in this analysis. Healthcare is free for all pregnant women and infants (up to age 2 years) in France. We showed previously that more African immigrants than French-born women underwent HIV screening late in their pregnancies, but that access to mother-to-child transmission of HIV prevention, once the infection was diagnosed, is similar for the 2 groups [39] . These observations suggest that the association with serious bacterial infections is not solely due to differential access to care according to maternal geographical origin.
Our analysis provides strong evidence for a relationship between low maternal CD4 count and serious bacterial infections of the lung. Infections with encapsulated bacteria are clearly suggestive of weakened humoral immunity. The absence of association with viral infections suggests that cellular immunity is not clinically affected. Because the relationship remained significant in sensitivity analyses after adjustment for infant CD4 values, the association cannot be explained by a direct effect on newborn CD4 cell counts. The apparent humoral immune defect could be due to an altered mother-to-child IgG transfer through the placenta, as described previously [25] , or to intrinsic humoral deficiency. In a well-designed study, the production of specific antibodies after immunization was normal or even higher in HEU infants than in control infants [25] . Although most events occurred during the first 3 months of life, the association with maternal CD4 count continued beyond the neonatal period and throughout the first year of life. The duration of protection by maternal antibodies has not been clearly established. The half-life of IgG is around 20 days, and the protective effect of such antibodies in infants is likely to last for several half-lives. Infectious morbidity in infants born to hypo-or agammaglobulinemic mothers, and before the child can develop effective humoral immunity, is well known but has never been rigorously described before the use of intravenous immunoglobulins. By contrast, the Bruton disease model is informative and well described [40] . Boys with this congenital X-linked disease are unable to produce antibodies and are agammaglobulinemic; the first infection rarely occurs before age 6 months and most patients present their first infection at age 6-12 months, clearly showing that maternal antibodies are protective until approximately this age.
The infectious-related mortality rate in France is low but may well be higher in low-resource settings and countries.
Prolonged antibacterial prophylaxis during infancy and/or maternal immunization against pneumococcus and haemophilus infection could be proposed during pregnancy. Early immunization for such infants may also be beneficial.
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